Pharmaceuticals News and Research

RSS

Third-quarter 2009 results announced by Catalyst Pharmaceutical

Catalyst Pharmaceutical Partners, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

12 Nov 2009

American Medical Alert announces operating results for the third quarter of 2009

American Medical Alert Corp. a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter and nine months ended September 30, 2009.

12 Nov 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.

12 Nov 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.

12 Nov 2009

MAP Pharmaceuticals to sell up to $60 million of its registered common stock to Azimuth Opportunity

MAP Pharmaceuticals, Inc. today announced that it has secured a committed equity financing facility under which it may sell up to $60 million of its registered common stock to Azimuth Opportunity Ltd. MAP Pharmaceuticals is not obligated to utilize any of the $60 million facility, which has a term of 24 months.

12 Nov 2009

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for Development.

12 Nov 2009

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

Bradmer Pharmaceuticals Inc. today announced its 2009 third quarter financial results.

12 Nov 2009

Jonathan Richman to present at FDA public hearing on promoting medical devices using the Internet

Bridge Worldwide announced today that Jonathan Richman, Director of Strategic Planning, will present at the public hearing on "Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools," to be held on November 12 and 13, 2009, from 8 a.m. to 5 p.m., at the National Transportation Safety Board Conference Center in Washington, D.C. Richman is scheduled to speak on Friday, November 13, at 11:40 a.m. and 2:40 p.m. for 10 minutes per time slot. To listen to a free, live webcast of the hearing, go to: www.capitolconnection.net/capcon/fda/111209/FDAlive.htm.

12 Nov 2009

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Chief Research Officer Morris S. Whitcup, Ph.D., of ORC Guideline (an infoGROUP company) (NASDAQ: IUSA) will present findings of the company’s recent research on the impact of social media on fair balance and pharmaceutical marketing at a Food and Drug Administration (FDA) public hearing later this week. The hearing will address the issue of fulfilling requirements for fair balance and risk disclosure in internet and social media promotions. The ORC Guideline study examined consumer habits in researching information about pharmaceutical products online.

12 Nov 2009

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.

12 Nov 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

IMS Health to launch comprehensive analytical tool for oncology market

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology QuantifierTM, a comprehensive, clinically rich analytical tool that enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion global oncology market.

12 Nov 2009

UMass Memorial Health Care renews its supply chain relationship with Broadlane

Broadlane, the leading cost-management company for healthcare providers, announced today that UMass Memorial Health Care, the largest healthcare system in Central and Western Massachusetts, has renewed its supply chain relationship with Broadlane for another three years.

12 Nov 2009

Results from an analysis emphasizes the financial burden of SMI on the criminal justice and HHS systems

Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on the criminal justice and health and human services (HHS) systems, and may provide useful information to policy makers.

12 Nov 2009

New research center established to improve cardiac safety

The University of Rochester Medical Center has announced the creation of a new center that will assist researchers studying the electrical activity of the heart with the goal of improving drug safety, understanding cardiac arrhythmias, and developing new electrocardiograph technologies.

12 Nov 2009

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.

12 Nov 2009

Pharmaceuticals News and Research

Third-quarter 2009 results announced by Catalyst Pharmaceutical

American Medical Alert announces operating results for the third quarter of 2009

Update on Alnylam Pharmaceuticals' RNAi pipeline, platform, and technology

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

MAP Pharmaceuticals to sell up to $60 million of its registered common stock to Azimuth Opportunity

Review of Mersana Therapeutics's lead compound, XMT-1001 to be published

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

Jonathan Richman to present at FDA public hearing on promoting medical devices using the Internet

ORC Guideline's recent research on the impact of social media and pharmaceutical marketing

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Stapled Peptides directly inhibit the Notch transcription factor complex

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Stapled Peptides can inhibit key intracellular biological targets, says new research

Nuvo Research announces new licensing agreement for Oxoferin

IMS Health to launch comprehensive analytical tool for oncology market

UMass Memorial Health Care renews its supply chain relationship with Broadlane

Results from an analysis emphasizes the financial burden of SMI on the criminal justice and HHS systems

New research center established to improve cardiac safety

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring